Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index; 14 of the 34 sources its claims cite were checked for support.

RETATRUTIDE USE IN THE TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) AND OBESITY: AN INTEGRATIVE REVIEW

Open access

Abstract

Obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) are major global public health challenges, being associated with increased morbidity, mortality, and healthcare costs. In this context, novel pharmacological therapies have been developed to promote significant weight reduction and improve metabolic and hepatic outcomes. Retatrutide, a triple agonist of the GLP-1, GIP, and glucagon receptors, has emerged as an innovative therapeutic approach due to its ability to simultaneously target multiple pathways involved in energy metabolism regulation. The aim of this study was to analyze the available scientific evidence regarding the use of retatrutide in the treatment of obesity and MASLD. This integrative literature review included studies published between 2016 and 2026, identified through searches in the MEDLINE/PubMed and ScienceDirect databases. Clinical trials, prospective studies, systematic reviews, and relevant publications addressing the topic were included. The analyzed evidence demonstrated that retatrutide promotes weight reductions exceeding 24%, in addition to significant improvements in metabolic, glycemic, and cardiovascular parameters. In patients with MASLD, substantial reductions in liver fat content, exceeding 80% at higher doses, were observed, along with high rates of normalization of hepatic fat levels. Compared with previously established incretin-based therapies, such as semaglutide and tirzepatide, retatrutide showed particularly promising results. In conclusion, retatrutide represents one of the most innovative pharmacological approaches currently under development for the treatment of obesity and MASLD, although long-term studies are still required to confirm its sustained efficacy and clinical safety.

Overview

CoChat Summary

TL;DR

This integrative review argues that retatrutide, a triple GLP-1/GIP/glucagon receptor agonist, is highly effective for obesity and shows promising reductions in hepatic fat in MASLD. The paper concludes that results are strong but long-term studies are still needed to confirm sustained efficacy, safety, and effects on harder clinical outcomes.

Key findings

  • In a randomized clinical trial of people with obesity or overweight plus comorbidities, 48 weeks of retatrutide produced mean weight reductions of 22.8% at 8 mg and 24.2% at 12 mg, with a clear dose-response relationship.
  • The paper reports that in MASLD, retatrutide led to hepatic fat reductions exceeding 80% at the highest doses evaluated after 24 weeks, with high rates of normalization of hepatic fat levels.
  • Compared with prior incretin therapies, the review states semaglutide achieved about 14.9% mean weight loss and tirzepatide up to 20.9%, while retatrutide showed greater weight loss, “exceeding 24%.”
  • The review says retatrutide also improved waist circumference, glycaemia, glycated haemoglobin, blood pressure, and other cardiometabolic parameters.

Methods

  • Integrative literature review of retatrutide for obesity and MASLD.
  • Searches were conducted in PubMed/MEDLINE and ScienceDirect for publications from January 2016 to June 2026; included English-language clinical trials, prospective studies, observational studies, and systematic reviews, plus relevant articles.
  • The final sample comprised nine publications; analysis was descriptive, comparative, and narrative, organizing findings into themes on mechanism of action, weight loss, hepatic fat reduction, and future perspectives.

Limitations

  • The paper states that most available data derive from phase 2 studies with relatively short follow-up periods, limiting conclusions about durability of benefit.
  • It says evidence remains limited for fibrosis regression, prevention of cirrhosis, long-term hepatic complications, prolonged safety, therapeutic adherence, and cost-effectiveness.
  • Evident from the text: the review is based on nine publications and uses a narrative synthesis, so its conclusions depend on a small, heterogeneous evidence base rather than pooled quantitative analysis.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.56238/sevened2026.020-072

Cites

0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

10 Valid · 1 Not valid · 15 Not checked · 6 Own results and interpretations

13 more claims · 2 with their cited sources checked

Create a free account to see all 32 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 11
  • Probably not a substantial claim. 3
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Citations

Cites

The publisher hasn’t deposited this paper’s reference list.

Metadata

Authors
Santos, G. V. D., Nascimento, E. D. S. R. D., Carvalho, R. O. V., Teixeira, M. S., Bezerra, P. T. M., Vieira, L. H. S., Bezerra, I. P., Salvadego, M. A. L. D. O., Alexandre, B. G. F., Nascimento, S. B. D., Nascimento, S. L. D. O. R., Moura, M., Bastos, F. D. O., Siqueira, A. L. D., Machado, F. M., Silva, I. P. E., Oliveira, A. C. G. D., Beltrão, C. A. M. D. S., Amestoy, H. B., Almeida, R. K. D., Grando, V. G., Neves, T. D. A., Neri, D. N., & Reis, T. D. S. O.
Affiliations
  • Universidade Federal de Santa Maria (BR)
  • Universidad María Auxiliadora (PE)
  • Universidade Luterana do Brasil (BR)
  • Universidade Federal de Goiás (BR)
  • Universidade Regional do Noroeste do Estado do Rio Grande do Sul (BR)
  • Universidade do Oeste Paulista (BR)
  • Universidade Evangelica de Goiás (BR)
  • Centro Universitário Fundação Assis Gurgacz (BR)
  • Universidade Federal do Pará (BR)
Venue
Pathways to Health: Innovations and Approaches in Health Sciences - 2nd Edition
Publisher
Seven Editora
Published
2026-07-09
OpenAlex
W7167834509
Cited by
0
References
0
FWCI
0.00
Type
book chapter
Language
en
Open access
Licence
cc-by-nc
Locations
Seven Editora eBooks (publishedVersion, cc-by-nc)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
retatrutide, non-alcoholic fatty liver disease, obesity, GLP-1 receptor agonists, GIP receptor agonist, glucagon receptor agonist, weight loss, hepatic steatosis, liver fat reduction, semaglutide, tirzepatide, incretin-based therapy, glycemic control, cardiovascular outcomes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: RETATRUTIDE USE IN THE TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) AND OBESITY: AN INTEGRATIVE REVIEW. https://app.cochat.ai/papers/10.56238/sevened2026.020-072
The paper
Santos, G. V. D., Nascimento, E. D. S. R. D., Carvalho, R. O. V., Teixeira, M. S., Bezerra, P. T. M., Vieira, L. H. S., Bezerra, I. P., Salvadego, M. A. L. D. O., Alexandre, B. G. F., Nascimento, S. B. D., Nascimento, S. L. D. O. R., Moura, M., Bastos, F. D. O., Siqueira, A. L. D., Machado, F. M., Silva, I. P. E., Oliveira, A. C. G. D., Beltrão, C. A. M. D. S., Amestoy, H. B., . . . Reis, T. D. S. O. (2026). RETATRUTIDE USE IN THE TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) AND OBESITY: AN INTEGRATIVE REVIEW. Pathways to Health: Innovations and Approaches in Health Sciences - 2nd Edition. https://doi.org/10.56238/sevened2026.020-072

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.